Clinical Research Directory

Inclusion Criteria: * Patients with type 1 diabetes who have been using a Dexcom or Abbott Libre glucose sensor (any model) for at least 14 days prior to the date of installation of the mylife YpsoPump, with at least 70% coverage, under the same sensor. * Patient for whom the diabetes specialist decides to initiate the mylife CamAPS FX hybrid closed loop. * Patient who received the information sheets and gave their consent to participate in the study and to the processing of their personal data. * Adult patient who signed an informed consent form to participate in the study or minor patient whose parents signed an informed consent form for their child's participation in the study. * Adult patient, minor patient old enough to complete the questionnaires or parent of a minor patient able to read and understand French. * Adult patient / minor patient capable to complete the questionnaires or parent of a minor patient who agrees to complete the online self-questionnaires. Exclusion Criteria: * Patient who used a hybrid closed-loop system, a fully closed-loop system, or a do-it-yourself loop system, regardless of the brand or model, within the past 6 months. * Patients participating or having participated in a clinical trial in the previous month that prevents them from participating in other studies. * Patient or parent unable to give consent. * Protected Patient (subject to a legal protection measure: guardianship, curatorship or legal safeguard). * Patient with a contraindication to the prescription of the mylife CamAPS FX hybrid closed-loop ( according to the Instructions For Use, IFU). * Patient with an unresolved skin condition in the area of sensor placement and/or in the tubing placement area (e.g. psoriasis, dermatitis herpetiformis, rash, staphylococcal infection). * Patient with unstable diabetic retinopathy requiring laser treatment. * Patient with a concomitant condition or treatment that alters glucose metabolism and that, in the investigator's judgment, is likely to have a significant impact on glycemic control; * Patient whose follow-up cannot be carried out by the centre (relocation planned within 12 months of inclusion).